firstwordpharma.com
Lilly's Omvoh lacks differentiation; AbbVie's Skyrizi set to flourish in Crohn's disease
Cure8 flagged this item because the article title and available source metadata connect it to Crohn's disease, Inflammatory bowel disease, Risankizumab, and IL-23 inhibitor. We do not yet have enough reliable article text to summarize the details.
This may be most useful for Clinicians and Patients On Biologics following Crohn's disease, Inflammatory bowel disease, Risankizumab, IL-23 inhibitor, and Medications.
What To Know
Cure8 does not have enough reliable source text to summarize this article yet. Based on the article title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, Risankizumab, and IL-23 inhibitor. Use the original source link for the full details.
Because the source may be tied to a company, announcement, or business update, it is worth reading the original article for context and limitations.
